Nielsen H J, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J
Dept. of Surgical Gastroenterology, Hvidovre University Hospital, Denmark.
Scand J Gastroenterol. 2001 Mar;36(3):265-9. doi: 10.1080/003655201750074537.
Crohn disease is considered a consequence of inappropriate upregulation of immune reactions evoked by the intestinal microflora or luminal antigens. Since the intestinal mucosa is continuously exposed to tetanus toxoid we studied the antibody response to tetanus toxoid booster immunization in patients with Crohn disease and the subsequent release of various inflammatory mediators and growth factors in blood.
Ten patients with inactive disease and no concurrent medication and 12 age-and gender-matched healthy volunteers with anti-tetanus antibody levels less than 0.1 IU/ml were inoculated with 1 ml (6 Lf units) of tetanus toxoid vaccine. The anti-tetanus antibody levels were determined in serum obtained before inoculation and after 7, 14 and 28 days, respectively. C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), histamine, vascular endothelial growth factor (VEGF), tissue inhibitor of metalloproteinases-1 (TIMP-1), plasminogen activator inhibitor type-1 (PAI-1) and myeloperoxidase (MPO) were determined in serum or plasma obtained on the same days.
After inoculation anti-tetanus antibody levels were equally raised in patients and healthy volunteers. Pre-inoculation CRP levels were below the upper level of the normal range (<10 mg/l) in all inoculated patients/volunteers. No differences in IL-6, TNF-alpha, MPO or histamine levels between patients and healthy volunteers were observed. CRP levels were within the normal range and IL-6, TNF-alpha, MPO and histamine levels were unchanged in patients and volunteers during the study period. The levels of VEGF, TIMP-1 and PAI-1 were unchanged in the healthy volunteers during the study period, but were significantly (P < 0.05) increased at day 14 in patients with Crohn disease. At day 28 the levels had fallen to pre-inoculation levels, apart from PAI-1, which was still significantly (P<0.05) increased.
In patients with inactive Crohn disease, booster immunization against tetanus toxoid seems to result in normal anti-tetanus antibody synthesis, but it may cause inappropriate release of certain bioactive substances, which are known to play a major role in modulation of the inflammatory response.
克罗恩病被认为是肠道微生物群或肠腔抗原引起的免疫反应不适当上调的结果。由于肠道黏膜持续暴露于破伤风类毒素,我们研究了克罗恩病患者对破伤风类毒素加强免疫的抗体反应以及随后血液中各种炎症介质和生长因子的释放情况。
10例病情处于缓解期且未同时服用药物的患者以及12名年龄和性别匹配、抗破伤风抗体水平低于0.1 IU/ml的健康志愿者接种了1 ml(6Lf单位)破伤风类毒素疫苗。分别在接种前以及接种后7天、14天和28天测定血清中的抗破伤风抗体水平。在同一天采集的血清或血浆中测定C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、组胺、血管内皮生长因子(VEGF)、金属蛋白酶组织抑制剂-1(TIMP-1)、纤溶酶原激活物抑制剂-1(PAI-1)和髓过氧化物酶(MPO)。
接种后,患者和健康志愿者的抗破伤风抗体水平均同样升高。所有接种的患者/志愿者接种前的CRP水平均低于正常范围上限(<10 mg/l)。未观察到患者和健康志愿者之间IL-6、TNF-α、MPO或组胺水平存在差异。在研究期间,患者和志愿者的CRP水平均在正常范围内,IL-6、TNF-α、MPO和组胺水平未发生变化。在研究期间,健康志愿者的VEGF、TIMP-1和PAI-1水平未发生变化,但克罗恩病患者在第14天时显著升高(P<0.05)。到第28天时,除PAI-1水平仍显著升高(P<0.05)外,其他水平均降至接种前水平。
在病情处于缓解期的克罗恩病患者中,破伤风类毒素加强免疫似乎可导致正常的抗破伤风抗体合成,但可能会导致某些生物活性物质的不适当释放,而这些物质已知在炎症反应调节中起主要作用。